Save on this medicine
Other brands with the same active ingredient
These brands contain the same active ingredient (Oseltamivir). Strength and form may differ — confirm substitution with your doctor or pharmacist before switching.
Indications & Uses
Influvir 75 mg is indicated for:
Dosage Reference
Reference Information Only
Dosages shown are general references from official sources. Always consult your doctor or pharmacist for personalized dosing.
Adults:
Oseltamivir Phosphate can be taken with or without food, though taking it with food may improve tolerability for some patients. For treatment of influenza in adults and adolescents 13 years and older, the recommended oral dose is 75 mg twice daily for 5 days, and treatment should begin within 2 days of the onset of influenza symptoms. The safety and efficacy of Oseltamivir for prophylaxis of influenza in pediatric patients younger than 13 years of age have not been established. For prophylaxis of influenza in adults and adolescents 13 years and older following close contact with an infected individual, the recommended oral dose is 75 mg once daily for at least 7 days, with therapy beginning within 2 days of exposure. For prophylaxis during a community outbreak of influenza, the recommended dose is 75 mg once daily; safety and efficacy have been demonstrated for up to 6 weeks, and protection lasts for as long as dosing continues.
Side Effects
The most frequently reported adverse events are nausea and vomiting. These events are generally mild to moderate in degree and usually occur within the first 2 days of treatment. Additional adverse events reported in fewer than 1% of patients taking Tamiflu for treatment include unstable angina, anemia, pseudomembranous colitis, humerus fracture, pneumonia, pyrexia, and peritonsillar abscess.
Cautions & Contraindications
Warnings & Precautions
General: There is no evidence that Tamiflu Phosphate is effective against illness caused by agents other than influenza viruses Types A and B. The efficacy of Tamiflu Phosphate in patients who begin treatment more than 40 hours after symptom onset has not been established. Hepatic Impairment: The safety and pharmacokinetics of Tamiflu Phosphate in patients with hepatic impairment have not been evaluated. Renal Impairment: A dose adjustment is recommended for patients whose serum creatinine clearance is below 30 mL/min.
Contraindications
This product is not suitable for anyone known to be hypersensitive to any of its ingredients.